Quick Answer: BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice. In preclinical research, it has been studied for effects on tissue repair, tendon healing, angiogenesis, and gastrointestinal protection. It is legal to purchase in the UK for research purposes and is not a controlled substance. It is not approved for human use by the MHRA.
What Is BPC-157?
BPC-157 — formally Body Protection Compound 157 — is a pentadecapeptide: a chain of exactly 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of approximately 1,419 Da. It is a synthetic analogue of a segment of the Body Protection Compound protein first isolated from human gastric juice by Professor Predrag Šikirić and his team at the University of Zagreb.
Unlike many research peptides that are fragments of endogenous hormones, BPC-157 has no known endogenous counterpart — it is a sequence selected for its stability and biological activity from within a larger gastric protein. This unusual origin contributes to one of its most important research properties: remarkable stability in human gastric juice, making it resistant to enzymatic degradation in ways that most peptides are not.
The compound has accumulated a substantial body of preclinical literature — over 100 peer-reviewed publications, the majority from Šikirić’s Zagreb laboratory — examining its effects across multiple organ systems in rodent and other animal models. For a deeper overview of its molecular identity, see our guide: What does BPC-157 come from?
How Does BPC-157 Work? Mechanism of Action
BPC-157’s effects in preclinical models appear to operate through several converging pathways rather than a single mechanism. Understanding these pathways is essential for interpreting the research literature accurately.
Angiogenesis via VEGFR2 Upregulation
Perhaps the most consistently documented mechanism is BPC-157’s ability to stimulate angiogenesis — the formation of new blood vessels — by upregulating vascular endothelial growth factor receptor 2 (VEGFR2). In tissue repair, adequate vascularisation is rate-limiting: without new capillary ingrowth, healing tissues are starved of oxygen and nutrients. Multiple animal studies have demonstrated that BPC-157 accelerates capillary growth into wounds and injured tendons, correlating with faster macroscopic healing outcomes (Sikiric et al., Curr Neuropharmacol, 2016; PMID: 26979942).
Nitric Oxide / cGMP Signalling
BPC-157 modulates the nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) signalling pathway. Nitric oxide plays a critical role in vasodilation, cellular signalling, and wound healing. Research in rodent models suggests BPC-157 can both protect against and counteract NO pathway dysregulation — exerting what the literature describes as a “stabilising” effect on NO signalling rather than simply upregulating or downregulating it.
Growth Hormone Receptor Interaction and Tendon Healing
In musculoskeletal research models, BPC-157 has been shown to interact with growth hormone receptor pathways, accelerating tendon-to-bone healing. A key review by Gwyer et al. (Cell Tissue Res, 2019; PMID: 30915550) documented its consistent acceleration of tendon repair across multiple animal models.
FAK-Paxillin Pathway and Cell Migration
At the cellular level, BPC-157 activates the focal adhesion kinase (FAK) — paxillin pathway, which governs cell migration. This is particularly relevant to wound healing, where the rate at which fibroblasts and endothelial cells migrate into the wound bed determines repair speed. For a detailed breakdown: How does BPC-157 work?
BPC-157 Research Areas: What the Preclinical Evidence Covers
Tendon and Ligament Healing
This is the most extensively studied application. Multiple rodent studies have demonstrated statistically significant acceleration of Achilles tendon, rotator cuff tendon, and medial collateral ligament healing with BPC-157 administration. Improvements in tensile strength, histological organisation of collagen fibres, and time to functional recovery have all been documented. The angiogenic and FAK-paxillin mechanisms described above are the proposed drivers. For more detail: Does BPC-157 help tendon healing?
Gastrointestinal Protection
Given its origin in gastric juice, BPC-157’s gastroprotective properties are among its most thoroughly characterised. Sikiric et al. (Curr Pharm Des, 2011; PMID: 21548867) documented its ability to counteract NSAID-induced gastric lesions, protect against ethanol-induced damage, and accelerate healing of established ulcers in rodent models. See also: How does BPC-157 work in promoting gut health?
General Wound Healing and Tissue Repair
Beyond tendons, BPC-157 has been studied in models of skin wound healing, bone repair, corneal injury, and muscle damage. The common thread is acceleration of the proliferative phase of healing — BPC-157-treated animals consistently show faster closure, more organised extracellular matrix, and improved functional recovery vs controls. See: Does BPC-157 heal injuries? and What are the benefits of BPC-157?
Neurological and Brain-Gut Axis Research
A significant portion of the published literature examines BPC-157’s effects on the central nervous system via the brain-gut axis. In rodent models, it has been studied in the context of dopamine and serotonin system modulation, neuroprotection against toxins, and counteraction of withdrawal behaviours. These findings position BPC-157 as a potential research tool for neuro-gastrointestinal axis studies.
Anti-inflammatory Effects
BPC-157 has demonstrated anti-inflammatory properties in animal models, reducing inflammatory markers including NF-κB activation, cyclooxygenase-2 expression, and pro-inflammatory cytokine levels. This is relevant to its healing applications — chronic inflammation is a key impediment to tissue repair, and BPC-157’s ability to modulate this response may underpin many of its observed effects.
BPC-157 Legal Status in the UK (2026)
BPC-157 occupies a specific regulatory position in the UK. It is not a controlled substance under the Misuse of Drugs Act 1971 and does not fall within the scope of the Psychoactive Substances Act 2016. It is not listed on any MHRA prescription-only or pharmacy medicine schedule.
What BPC-157 is not: it is not licensed as a medicine in the UK or EU. The MHRA has not approved it for any clinical indication, and it cannot lawfully be marketed for human consumption, sold as a supplement, or prescribed by a GP. No NHS prescribing pathway exists.
What BPC-157 is: a research chemical that is legal to purchase, possess, and use for legitimate laboratory and scientific research purposes in the UK. Suppliers may sell it with clear “for research use only / not for human consumption” labelling in full compliance with UK regulatory requirements. For the broader picture of peptide law in the UK, see: Are peptides legal in the UK?
BPC-157 Forms: Acetate vs Arginate
BPC-157 Acetate
The acetate salt is the most common form in the literature and in commercial supply. It is the form used in the majority of published preclinical studies, making it the standard reference form for researchers wishing to replicate or build on existing findings. Typical lyophilised purity should be ≥98% by HPLC. It is reconstituted with bacteriostatic water or 0.9% acetic acid (the latter can improve stability in solution for some protocols).
BPC-157 Arginate Salt (BPC-157 Stable)
BPC-157 Arginate incorporates an arginine moiety, which is reported to increase aqueous stability and potentially improve oral bioavailability in animal models. The arginate form is of particular interest in gastrointestinal research where oral administration routes are being studied. The trade-off is that the literature base for arginate is thinner than for the acetate form.
BPC-157 vs TB-500: Key Differences for Researchers
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Compound type | Synthetic pentadecapeptide (15 AA) | Synthetic analogue of Thymosin Beta-4 (43 AA fragment) |
| Origin | Derived from human gastric juice protein | Derived from naturally occurring Thymosin Beta-4 |
| Primary mechanism | VEGFR2/angiogenesis, NO/cGMP, FAK-paxillin | Actin polymerisation, cell migration (G-actin sequestration) |
| Key research areas | Tendon/ligament, gut protection, neurological, wound healing | Muscle repair, cardiac tissue, wound healing, inflammation |
| Endogenous equivalent | None (no direct endogenous counterpart) | Yes — Thymosin Beta-4 is naturally produced |
For a full comparison: BPC-157 vs TB-500: Which Peptide Is Better for Healing?
BPC-157 Safety Profile: What the Research Shows
Within the preclinical literature, BPC-157 has a notably clean safety profile. Studies have tested it across oral, subcutaneous, intraperitoneal, and intravenous routes in rodent models without reporting significant toxic effects. No studies have identified a lethal dose in animal models at pharmacologically relevant doses. There are no documented organ toxicity signals in the published literature.
The important caveat: the absence of reported toxicity in animal models does not establish human safety. No completed Phase 2 or Phase 3 clinical trials exist for BPC-157 specifically, meaning extrapolation to human safety profiles is speculative.
For a comprehensive review: Is BPC-157 Safe for Scientific Research? and BPC-157 Side Effects: What Researchers Need to Know
BPC-157 Timeline in Research Models
- Angiogenesis initiation: VEGFR2 upregulation and early capillary ingrowth observed within 48–72 hours in wound healing models
- Tendon repair acceleration: Statistically significant improvements in healing vs control typically evident by day 7–14 in rodent tendon transection models
- Gastric lesion healing: Measurable reductions in ulcer size observed within 24–48 hours in acute rodent models
- Functional recovery: Improved strength/function measurements in musculoskeletal models typically at 3–6 weeks vs control
For more detail: When Does BPC-157 Start Working in Tissue Regeneration? and How Long Does BPC-157 Take to Work?
Storage and Reconstitution of BPC-157 for Laboratory Use
Storage Guidelines
- Lyophilised powder (unreconstituted): Store at -20°C for long-term stability (up to 24 months). Short-term storage at 2–8°C is acceptable for up to 3 months. Protect from light and humidity.
- Reconstituted solution: Store at 2–8°C. Use within 28 days. Do not freeze reconstituted solution. Protect from light.
Reconstitution Protocol
- Use bacteriostatic water (sterile water with 0.9% benzyl alcohol) for most laboratory applications
- Add bacteriostatic water slowly down the side of the vial — do not inject directly onto the lyophilised powder cake
- Swirl gently to dissolve — do not shake or vortex (this can denature the peptide)
- Allow to dissolve at room temperature; if residue remains, place in refrigerator for 15 minutes and swirl again
- A correctly reconstituted solution should be clear and colourless
For full storage and solubility protocols: BPC-157 Storage and Solubility Tips for Laboratory Use
Sourcing Research-Grade BPC-157 in the UK
The purity and integrity of BPC-157 used in research directly affects the reliability of results. The minimum standards for research-grade BPC-157 are:
- Purity ≥98% as verified by HPLC — not just mass spectrometry, which cannot detect closely related impurities
- Mass confirmation by LC-MS or MALDI-TOF confirming the correct molecular weight (1,419.53 Da for BPC-157 acetate)
- Batch-specific Certificate of Analysis (COA) — a generic COA not linked to the specific production batch is insufficient
- Endotoxin testing for in-vivo applications (LAL or equivalent)
Why UK-Dispatched Supply Matters
Peptides are temperature-sensitive. International shipments expose material to potentially uncontrolled temperature excursions during transit. UK-dispatched BPC-157, stored in temperature-controlled conditions and shipped domestically, eliminates cold-chain risk. It also removes import duty and customs delay considerations.
Peptides Lab UK supplies independently HPLC-tested, batch-COA-verified BPC-157 Acetate and BPC-157 Arginate dispatched directly from UK stock. Every batch is tested by an independent third-party laboratory with results available on request. Products are clearly labelled for research use only, in full compliance with UK regulatory requirements.
BPC-157 Supporting Research: The Complete Cluster
- What does BPC-157 do?
- What type of peptide is BPC-157?
- How does BPC-157 work?
- What are the benefits of BPC-157?
- Does BPC-157 heal injuries?
- Does BPC-157 help tendon healing?
- Is BPC-157 a Growth Factor?
- How Long Does BPC-157 Take to Work?
- When Does BPC-157 Start Working in Tissue Regeneration?
- BPC-157 Side Effects: What Researchers Need to Know
- Is BPC-157 Safe for Scientific Research?
- BPC-157 Storage and Solubility Tips for Laboratory Use
- How does BPC-157 work in promoting gut health?
- BPC-157 vs TB-500: Which Peptide Is Better for Healing?
Frequently Asked Questions: BPC-157 UK Research
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — a sequence of 15 amino acids — derived from a protective protein found in human gastric juice. It is used exclusively in preclinical and laboratory research settings and is not approved for human use by the MHRA.
Is BPC-157 legal in the UK?
BPC-157 is not a controlled substance under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is legal to purchase and possess in the UK for legitimate research purposes. It is not licensed as a medicine by the MHRA and cannot be sold for human consumption.
What does BPC-157 do in research models?
In preclinical research, BPC-157 has been shown to accelerate wound healing, promote tendon and ligament repair, protect gastric mucosa, modulate nitric oxide signalling, stimulate angiogenesis, and exert neuroprotective effects. These findings are from animal studies; no completed human clinical trials exist.
What is the difference between BPC-157 Acetate and BPC-157 Arginate?
BPC-157 Acetate is the most common form, used in the majority of published studies. BPC-157 Arginate incorporates an arginine moiety that is reported to improve aqueous stability and potentially oral bioavailability. The acetate form is the standard for researchers replicating existing literature; the arginate form may be preferred for gastrointestinal oral-route protocols.
What purity should I require for research-grade BPC-157?
A minimum of 98% purity by HPLC, confirmed by a batch-specific Certificate of Analysis. For in-vivo protocols, additionally require endotoxin testing results. Mass spectrometry confirmation of correct molecular weight (1,419.53 Da for acetate) should also be provided.
Source Research-Grade BPC-157 in the UK
Peptides Lab UK supplies independently HPLC-tested, batch-COA-verified BPC-157 Acetate and BPC-157 Arginate dispatched from UK stock. Every product is clearly labelled for research use only, in full compliance with UK regulatory requirements — no prescription required for laboratory purchase. View the verified BPC-157 range at Peptides Lab UK →
For research purposes only / not for human consumption.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified BPC-157 for research and laboratory use — from £17.99. View UK stock →
